Literature DB >> 7491124

Genotoxic potential of beta-carbolines: a review.

C de Meester1.   

Abstract

The mutagenic and co-mutagenic properties of harman, norharman and of some of their pharmacologically important derivatives are reviewed. These compounds do not behave as true mutagens, but rather interact, directly or indirectly with DNA, leading to various consequences. This unusual behaviour is most probably related to the particular structure of the chemical nucleus common to all beta-carbolines which confers to the different derivatives the property to interact with various macromolecules and enzymatic systems. These interactions are compiled and discussed in this review. The alterations, by beta-carbolines, of some important enzymatic systems, e.g. cytochrome P-450, have been clearly demonstrated, yet many discrepancies and contradictions exist so that an interpretation of the results and the definition of some common mechanism appears premature. Since beta-carbolines are widely distributed in tissues and since they may modify and increase genotoxic and toxic consequences of other compounds, these interactions need to be clarified.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491124     DOI: 10.1016/0165-1110(95)90008-x

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  17 in total

1.  Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).

Authors:  Tatyana Adayev; Jerzy Wegiel; Yu-Wen Hwang
Journal:  Arch Biochem Biophys       Date:  2010-12-24       Impact factor: 4.013

2.  A spectroscopic study of the interaction of the fluorescent beta-carboline-3-carboxylic acid N-methylamide with DNA constituents: nucleobases, nucleosides and nucleotides.

Authors:  Iñigo X García-Zubiri; Hugh D Burrows; Joao S Seixas de Melo; María Monteserín; Antonio Arroyo; María J Tapia
Journal:  J Fluoresc       Date:  2008-05-11       Impact factor: 2.217

3.  Blood harmane concentrations and dietary protein consumption in essential tremor.

Authors:  E D Louis; W Zheng; L Applegate; L Shi; P Factor-Litvak
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

4.  Harmines inhibit cancer cell growth through coordinated activation of apoptosis and inhibition of autophagy.

Authors:  Xinran Geng; Yichang Ren; Fangfang Wang; Danmei Tian; Xinsheng Yao; Youwei Zhang; Jinshan Tang
Journal:  Biochem Biophys Res Commun       Date:  2018-03-01       Impact factor: 3.575

5.  DNA-binding studies of the natural β-carboline eudistomin U.

Authors:  Jennifer M Giulietti; Patrick M Tate; Ang Cai; Bongsup Cho; Seann P Mulcahy
Journal:  Bioorg Med Chem Lett       Date:  2016-08-18       Impact factor: 2.823

6.  Dietary epidemiology of essential tremor: meat consumption and meat cooking practices.

Authors:  Elan D Louis; Garrett A Keating; Kenneth T Bogen; Eileen Rios; Kathryn M Pellegrino; Pam Factor-Litvak
Journal:  Neuroepidemiology       Date:  2008-04-02       Impact factor: 3.282

7.  Cancer and blood concentrations of the comutagen harmane in essential tremor.

Authors:  Elan D Louis; Kathryn M Pellegrino; Pam Factor-Litvak; Eileen Rios; Wendy Jiang; Claire Henchcliffe; Wei Zheng
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

8.  Ground and singlet excited state pyridinic protonation of N9-methylbetacarboline in water-N,N-dimethylformamide mixtures.

Authors:  Antonio Sánchez Coronilla; Carmen Carmona; María A Muñoz; Manuel Balón
Journal:  J Fluoresc       Date:  2009-06-18       Impact factor: 2.217

9.  Elevated brain harmane (1-methyl-9H-pyrido[3,4-b]indole) in essential tremor cases vs. controls.

Authors:  Elan D Louis; Pam Factor-Litvak; Xinhua Liu; Jean-Paul G Vonsattel; Monika Galecki; Wendy Jiang; Wei Zheng
Journal:  Neurotoxicology       Date:  2013-08-02       Impact factor: 4.294

Review 10.  Environmental epidemiology of essential tremor.

Authors:  Elan D Louis
Journal:  Neuroepidemiology       Date:  2008-08-21       Impact factor: 3.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.